Healthcare Business Update: Alexion’s Takeover CHATTER, Lilly Wins PATENT Suit Against Teva

The rumored acquisition of Shares of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) by Roche (RHHBY) sent shares of the former higher again on Friday. A Seeking Alpha article is likely to have given the process a boost, by suggesting tha shares are set to move higher whether there is a buyout or not. Contributor Supreme Alpha contends that Alexion has a solid earnings per share and respective revenue growth rates of 37 percent and 46 percent, which he considers the actual movers behind the stock’s outperformance.

Eli Lilly and Company’s (NYSE:LLY) patent case against Teva Pharmaceutical Industries Limited (NYSE:TEVA) saw an appeals court affirm the favorable ruling, deciding that the claims of Lilly’s Alimta compound patent are not invalid. Additionally, the court said that it “considered each of Teva’s remaining arguments and find them unpersuasive.” The compound patent in question covers the drug domestically through January of 2017.

Want news like this in real-time so you can get an edge? Click here for Wall St. Cheat Sheet Pro.